Short answer: Metformin has a plausible AMPK/mTOR longevity mechanism and intriguing observational data in diabetics — but the definitive TAME trial in non-diabetic adults remains funding-stalled with no participants enrolled, so off-label longevity use is still ahead of the evidence designed to answer this question.
Metformin might be the most-discussed anti-aging drug that isn't actually being tested for anti-aging — at least not yet. The trial designed specifically to answer whether it extends human healthspan has been ready to go since 2016 and still hasn't enrolled a single participant. Here's the real state of the evidence behind one of longevity medicine's most talked-about off-label uses.
What Metformin Is Actually FDA-Approved For
Metformin is an oral biguanide drug the FDA originally approved on March 3, 1995 (as Glucophage), indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Metformin's FDA-approved indication remains limited to type 2 diabetes. It has no FDA approval for prediabetes, weight management, PCOS, or any anti-aging or longevity purpose — use for any of those is off-label.
The Mechanistic Case for Longevity
Interest in metformin for longevity stems from a real, well-characterized mechanism: metformin inhibits mitochondrial Complex I, which raises the cellular AMP-to-ATP ratio and activates AMP-activated protein kinase (AMPK) — the same energy-sensing pathway activated by caloric restriction and exercise, both established lifespan-extending interventions in animal models.[1]
Downstream of AMPK activation, metformin also suppresses mTOR signaling, restores autophagy, improves mitochondrial function, and reduces senescence-associated inflammatory signaling — a combination of effects that touches several recognized biological "hallmarks of aging."[1]
The Human Data That Started the Conversation
The finding that sparked broad scientific interest came from a 2014 UK analysis of roughly 180,000 patients, which found that type 2 diabetics treated with metformin monotherapy had lower all-cause mortality than matched non-diabetic control patients without diabetes at all (hazard ratio 0.85) — meaning treated diabetics appeared to outlive people who never had diabetes in the first place.
A 2017 systematic review and meta-analysis further found diabetics on metformin had significantly reduced all-cause mortality compared to non-diabetics, lower cancer incidence compared to non-diabetics, and reduced cardiovascular risk compared to diabetics on other treatments.[2]
These findings are genuinely striking, but it's important to be precise about their limits: they come from observational studies in diabetic populations, and are subject to potential unmeasured confounding — metformin users may differ systematically from comparison groups in ways the underlying databases don't capture. That limits how directly these findings can be extrapolated to healthy, non-diabetic adults taking metformin specifically for longevity.
MILES: The Small Pilot That Came Next
To test metformin's biological effects more directly, researchers at Albert Einstein College of Medicine conducted the Metformin in Longevity Study (MILES) — a completed pilot trial that treated 16 older adults with impaired glucose tolerance with metformin (1,700 mg/day) for 6 weeks, examining whether it produced gene-expression changes associated with younger, healthier tissue.[3]
MILES found that metformin altered multiple aging-associated pathways in muscle and fat tissue, including metabolic pathways, extracellular matrix remodeling, and genes involved in DNA mismatch repair. But the study authors themselves noted it remains controversial whether metformin is protective in people who are otherwise free of disease.[3]
TAME: The Trial Designed to Actually Answer This — Still Waiting to Start
To directly test the longevity hypothesis in a large, non-diabetic human population, the same research team designed the TAME (Targeting Aging with Metformin) trial — a proposed randomized, double-blind, placebo-controlled study intended to enroll approximately 3,000 non-diabetic adults aged 65–79 across roughly 14 U.S. research centers.[4]
TAME's design is genuinely novel for a pharmaceutical trial: rather than tracking a single disease outcome, its primary endpoint tracks time to the first occurrence of any of several age-related conditions — cardiovascular events, cancer, dementia, or death — a composite endpoint developed and agreed upon with the FDA back in 2015.[4]
Here's the part worth knowing clearly: as of August 2026, TAME remains stalled without a single participant enrolled, a decade after being proposed. The barrier isn't scientific — it's entirely financial. Because metformin is an off-patent generic drug, it doesn't attract the kind of commercial pharmaceutical sponsorship that funds trials of this scale, and the trial has spent years searching for philanthropic or public funding instead.[4]
What This Means for the Current Evidence
Because TAME hasn't launched and no positive randomized trial has yet demonstrated a longevity or healthspan benefit specifically in non-diabetic humans, the current evidence for metformin as an anti-aging intervention remains genuinely preliminary: supported by animal mechanistic data, human observational associations in diabetics, and one small human pilot biomarker study — but without a completed, definitive human efficacy trial in the actual population that would use it off-label for longevity.
Comparing providers? Seemetformin and metabolic-support pricing across Longevity providerson RENVA's Longevity hub.
The Bottom Line
Metformin has one of the more plausible mechanistic cases in the longevity space, backed by decades of safety data as an approved diabetes drug and some genuinely intriguing observational findings. But the trial specifically designed to test whether it works for healthy, non-diabetic people has been ready since 2016 and still hasn't enrolled anyone — which means anyone taking metformin off-label for longevity today is doing so ahead of the evidence that was specifically designed to answer this question, not because that evidence came back negative, but because it hasn't happened yet.
Sources
- Metformin as a Tool to Target Aging — PMC (National Institutes of Health), Barzilai N. et al. pmc.ncbi.nlm.nih.gov
- Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis — Ageing Research Reviews (ScienceDirect) sciencedirect.com
- Metformin in Longevity Study (MILES) — ClinicalTrials.gov (NCT02432287), Albert Einstein College of Medicine clinicaltrials.gov
- TAME — Targeting Aging with Metformin — American Federation for Aging Research (official trial page) afar.org
Frequently Asked Questions
Is metformin FDA-approved for anti-aging?
No. Metformin is FDA-approved only for type 2 diabetes. Any use for prediabetes, weight management, PCOS, or longevity is off-label.
What is the TAME trial, and has it started?
TAME (Targeting Aging with Metformin) is the trial designed to directly test whether metformin extends healthy human lifespan. As of August 2026, it has not enrolled any participants due to a decade-long funding search, since metformin's off-patent status means no pharmaceutical company will sponsor the trial.
Does metformin actually extend lifespan in humans?
This hasn't been directly tested yet. The evidence so far comes from observational studies in people who already have diabetes, plus animal and small pilot human data — not a completed trial in healthy, non-diabetic adults.